Wow, last $1.82 up 13 cents on even stronger volume thanyesterday. This news release was not one of the big ones expected, but any chance for Matt to tell the story of how Pelareorep is different from all other oncolytic viruses is a welcome thing! There had been a lot of excitement around oncolytic viruses, but some of the others delivered ho hum results, had to be injected directly into the tumor, had to be handled as biohazardous material, etc.
ONC's drug is differentiated in ever single way but most importantly SAFETY and EFFICACY. It has the potential to be standard of care as an adjuvant therapy in the massive immunoncology market....